Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-Kids phase 3b trial of lerodalcibep in children and adolescents with heterozygous familial hypercholesterolemia
MOH_2026-04-13_015763Phase 3Not yet recruiting
- Sponsor
- LIB Therapeutics, LLC
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Lerodalcibep with Placebo (2 arms). Primary endpoints: Change in LDL-C at 6 months after first dose and Efficacy of lerodalcibep versus placebo. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
lerodalcibep
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on MOH_2026-04-13_015763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-13_015763.